EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Survival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study

Rafael Conde-Camacho iD, Eduardo Tuta-Quintero iD, Mauricio González iD, Wendy Rubiano, Emily Rincón iD, Katherine Diaz, Luis F Giraldo-Cadavid iD

Pulmonary Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/pm/2867844 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pulmonary Medicine, online erschienen am 19.05.2026. Verfasst von Rafael Conde-Camacho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Doctoral, Universidad de La Sabana, Chía, Colombia, unisabana.edu.co. Hauptthemen laut MEDLINE: Prostaglandins, Hemodynamics, Hypertension, Pulmonary, Altitude. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de La Sabana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Latin America, the evidence regarding the use of prostanoids at high altitude in patients with Group 1 pulmonary hypertension (PH‐1) is limited. Therefore, it is essential to describe the clinical characteristics and outcomes associated with prostanoid treatment in this population.

Methods

This retrospective study involved patients with PH‐1. Hemodynamic and clinical variables were compared before the initiation of prostanoids and during clinical follow‐up. Overall survival was analyzed using Kaplan–Meier estimation, with survival rates calculated at 3 and 5 years. The strength of the association for each variable concerning the proposed outcomes was estimated by calculating the odds ratio (OR).

Results

The study included 55 patients (mean age 34.6 ± 10.3 years), 83.6% women, all receiving triple combination therapy with endothelin receptor antagonists (ERAs), phosphodiesterase Type 5 inhibitors, and parenteral prostacyclin analogues. Idiopathic pulmonary arterial hypertension was present in 62%, and 60% were classified as intermediate risk at baseline. Median time from PH‐1 diagnosis to prostacyclin initiation was 8.96 months (IQR 1.88–41.42). At 1 year, complete follow‐up data were available for 49 patients. St. George′s Respiratory Questionnaire scores improved significantly from 49.0 to 36.5 at 1 year and 31.5 at the last follow‐up ( p < 0.001). Cardiac index increased from 2.24 to 2.96 L/min/m 2 at 1 year ( p < 0.001), whereas mixed venous oxygen saturation improved significantly. In survivors, the 6‐min walk test distance increased by 53.5 m, and pulmonary vascular resistance decreased by 3.8 WU. Diffusing capacity for carbon monoxide (DLCO) < 25% was associated with an OR of 7.35 (95% CI: 1.28–41.92; p = 0.015), and tricuspid annular plane systolic excursion to pulmonary artery systolic pressure ratio (TAPSE/PASP) < 0.10 mm/mmHg had an OR of 5.78 (95% CI: 0.64–52.03; p = 0.088). Female sex had an OR of 0.13 (95% CI: 0.02–0.78; p = 0.016). Three‐ and five‐year survival rates were 87.2% and 78.1%, respectively.

Conclusion

Parenteral prostanoids in patients with PH‐1 demonstrate improvements in hemodynamic variables during clinical follow‐up. A DLCO < 25% and a TAPSE/PASP < 0.10 mm/mmHg were associated with an increased risk of mortality, whereas female sex was identified as a protective factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstaglandinsHemodynamicsHypertension, PulmonaryAltitudeFamilial Primary Pulmonary HypertensionHumansFemaleRetrospective StudiesAdultMaleEndothelin Receptor AntagonistsEpoprostenolSurvival RatePhosphodiesterase 5 Inhibitors

Stichwörter der Autor:innen

parenteral prostanoidspulmonary hypertensionrisk factorsurvival

Substanzen

ProstaglandinsEndothelin Receptor AntagonistsEpoprostenolPhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Biosciences Doctoral, Universidad de La Sabana, Chía, Colombia, unisabana.edu.co.
  • Department of Pulmonary Hypertension, Fundación Neumológica Colombiana, Bogotá, Colombia.
  • School of Medicine, Universidad de La Sabana, Chía, Colombia, unisabana.edu.co.
  • Medical Department, Fundación Neumológica Colombiana, Bogotá, Colombia.

ORCID-Profile: Rafael Conde-Camacho, Eduardo Tuta-Quintero, Mauricio González, Emily Rincón, Luis F Giraldo-Cadavid

Förderung

  • Universidad de La Sabana

Zitieren

APA

Conde-Camacho, R., Tuta-Quintero, E., González, M., Rubiano, W., Rincón, E., Diaz, K., & Giraldo-Cadavid, L. F. (2026). Survival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study. Pulmonary Medicine, 2026(1). https://doi.org/10.1155/pm/2867844

Vancouver

Conde-Camacho R, Tuta-Quintero E, González M, Rubiano W, Rincón E, Diaz K, et al. Survival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study. Pulmonary Medicine. 2026;2026(1). doi:10.1155/pm/2867844

BibTeX
@article{CondeCamacho2026,
  author = {Conde-Camacho, Rafael and Tuta-Quintero, Eduardo and González, Mauricio and Rubiano, Wendy and Rincón, Emily and Diaz, Katherine and Giraldo-Cadavid, Luis F},
  title = {Survival and Hemodynamic Effects of Parenteral Prostanoids in High‐Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study},
  journal = {Pulmonary Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/pm/2867844}
}
Kostenlos starten →